{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:42:51Z","timestamp":1777956171742,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,31]]},"DOI":"10.7759\/cureus.21768","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T14:56:51Z","timestamp":1643641011000},"source":"Crossref","is-referenced-by-count":1,"title":["Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip"],"prefix":"10.7759","author":[{"given":"Marc T","family":"Zughaib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunjal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariola","family":"Leka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saif","family":"Affas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic diabetic ketoacidosis: a review","volume":"13","author":"Modi A","year":"2017","unstructured":"Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev. 2017, 13:315-21. 10.2174\/1573399812666160421121307","journal-title":"Curr Diabetes Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5660","article-title":"Diabetic ketoacidosis in adults","volume":"351","author":"Misra S","year":"2015","unstructured":"Misra S, Oliver NS. Diabetic ketoacidosis in adults. BMJ. 2015, 351:h5660. 10.1136\/bmj.h5660","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"143","author":"Packer M","year":"2021","unstructured":"Packer M, Anker SD, Butler J, et al.. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021, 143:326-36. 10.1161\/CIRCULATIONAHA.120.051783","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, et al.. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021, 384:129-39. 10.1056\/NEJMoa2030186","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato ET","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, et al.. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019, 139:2528-36. 10.1161\/CIRCULATIONAHA.119.040130","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.047480","article-title":"Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF","volume":"142","author":"Docherty KF","year":"2020","unstructured":"Docherty KF, Jhund PS, Anand I, et al.. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation. 2020, 142:1623-32. 10.1161\/CIRCULATIONAHA.120.047480","journal-title":"Circulation"},{"key":"ref11","unstructured":"US Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. (2015). Accessed. December 30, 2021: https:\/\/www.fda.gov\/media\/92185\/download."},{"key":"ref12","unstructured":"European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. (2016). Accessed. December 30, 2021: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/sglt2-inhibitors-article-20-procedure-ema-confirms-recommendations-mi...."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1251","article-title":"Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program","volume":"38","author":"Erondu N","year":"2015","unstructured":"Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015, 38:1680-6. 10.2337\/dc15-1251","journal-title":"Diabetes Care"},{"key":"ref14","article-title":"Euglycemic Diabetic Ketoacidosis","author":"Plewa MC","year":"2021","unstructured":"Plewa MC, Bryant M, King-Thiele R. Euglycemic Diabetic Ketoacidosis. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2021 Jan-."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020, 383:1413-24. 10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al.. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021, 384:117-28. 10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Langkilde, for the DAPA-HF Trial Committees and Investigators*. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et. al.. Langkilde, for the DAPA-HF Trial Committees and Investigators*. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.02.016","article-title":"Cardiometabolic effects of a new class of antidiabetic agents","volume":"37","author":"Desouza CV","year":"2015","unstructured":"Desouza CV, Gupta N, Patel A. Cardiometabolic effects of a new class of antidiabetic agents. Clin Ther. 2015, 37:1178-94. 10.1016\/j.clinthera.2015.02.016","journal-title":"Clin Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia DS","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017, 24:73-9. 10.1097\/MED.0000000000000311","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.020","article-title":"2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways","volume":"72","author":"Das SR","year":"2018","unstructured":"Das SR, Everett BM, Birtcher KK, et al.. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018, 72:3200-23. 10.1016\/j.jacc.2018.09.020","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman Y","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016, 22:753-62. 10.4158\/EP161292.PS","journal-title":"Endocr Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/82577-self-induced-euglycemic-diabetic-ketoacidosis-when-to-stop-the-drip","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:02Z","timestamp":1707507422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/82577-self-induced-euglycemic-diabetic-ketoacidosis-when-to-stop-the-drip"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.21768","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,31]]}}}